Starpharma Holdings LimitedASX: SPL

$3.5 Million R&D Tax Incentive Received

· Issued by Starpharma Holdings Limited via ASX

Filed with ASX · · 1 page · English

Summary by 6ix AI

CEO Cheryl Maley emphasized the importance of this incentive for supporting biotechnology innovation and advancing their dendrimer technology. The company focuses on high-impact oncology programs that aim to improve patient outcomes through their unique technology.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/dollar3.5-million-randd-tax-incentive-received

Release

ASX Announcement $3.5 Million R&D Tax Incentive Received Melbourne, Australia; 22 October 2026: Starpharma (ASX: SPL, US OTC: SPHRY), an innovative biotechnology company advancing dendrimer technology from the lab to the patient, today announces the receipt of $3.5 million under the Australian...

Starpharma Holdings Limited on 6ix

In the deck

Story so far

Earlier from Starpharma

Later from Starpharma

All Starpharma news releases